Skip to content

Upstream Bio, Inc. UPB Book value per share

Book value per share at other companies

Amgen logo
AmgenAMGN
$16.89+47.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$291.77+10.4%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.12-5.3%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$0.85-35.6%
Savara logo
SavaraSVRA
$0.70+1.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0.44-60.0%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s book value per share?
Upstream Bio, Inc. (UPB) reported book value per share of $5.60 in Q1 2026.
How has Upstream Bio, Inc.'s book value per share changed year-over-year?
Upstream Bio, Inc.'s book value per share decreased by 32.7% year-over-year, from $8.31 to $5.60.
What is the long-term trend for Upstream Bio, Inc.'s book value per share?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s book value per share has grown at a -61.1% compound annual growth rate (CAGR), from -$41.68 to $6.31.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.